LASP-1 is a multidomain protein predominantly localized at focal contacts, where it regulates cytoskeleton dynamics and cell migration. However, in different tumor entities, a nuclear LASP-1 accumulation is observed, thought to have an important role in cancer progression. Until now, the molecular mechanisms that control LASP-1 nuclear import were not elucidated. Here, we identified a novel LASP-1-binding partner, zona occludens protein 2 (ZO-2), and established its role in the signal transduction pathway of LASP-1 nucleo-cytoplasmatic shuttling. Phosphorylation of LASP-1 by PKA at serine 146 induces translocation of the LASP-1/ZO-2 complex from the cytoplasm to the nucleus. Interaction occurs within the carboxyterminal proline-rich motif of ZO-2 and the SH3 domain in LASP-1. In situ proximity ligation assay confirmed the direct binding between LASP-1 and ZO-2 and visualized the shuttling. Nuclear export is mediated by Crm-1 and a newly identified nuclear export signal in LASP-1. Finally, dephosphorylation of LASP-1 by phosphatase PP2B is suggested to relocalize the protein back to focal contacts. In summary, we define a new pathway for LASP-1 in tumor progression.
INTRODUCTION
The LIM and SH3 domain protein LASP-1 (earlier named MLN50) was initially identified from a cDNA library of breast cancer metastases. 1 Although LASP-1 protein is detected at low basal levels in all normal human tissues, 2 protein overexpression has been described in several types of cancer, for example, metastatic breast cancer, 3 ovarian cancer, 4, 5 colorectal cancer 6 and medulloblastoma. 7 LASP-1 is predominantly found at multiple sites of cytoplasmic actin assembly, including focal contacts, lamellipodia and membrane ruffles, 8 where it interacts with a number of motilityassociated proteins such as zyxin, dynamin, lipoma preferred partner (LPP), actin, paladin and Krp1 (for review see Grunewald and Butt 2 ). However, in tumor cells, an additional striking nuclear localization of the protein was observed. 9 Furthermore, LASP-1 expression and nuclear localization correlated significantly with tumor size, nodal positivity and a poor long-term survival of the patients. 6, 7, 9 Silencing of LASP-1 by RNA interference in various cell lines resulted in a strong inhibition of proliferation and migration with cell-cycle arrest in G2/M phase, whereas overexpression increased cancer cell proliferation, cell motility and the ability to form colonies. 4, 10 Recent studies revealed that specific phosphorylation at serine/ threonine and tyrosine regulates function and localization of LASP-1. Cyclic adenosine monophosphate-and cyclic guanosine monophosphate-dependent protein kinase (PKA and PKG)-mediated phosphorylation at Ser-146 reduces binding of LASP-1 to F-actin, increases translocation of the protein to the cytosol and decreases cell migration. 11, 12 Additionally, human LASP-1 is phosphorylated at tyrosine 171 by abelson tyrosine kinase 13 and Src kinase.
14 Phosphorylation by abelson tyrosine kinase is seen in apoptotic cells and specifically blocks LASP-1 translocation to focal complexes, 13 whereas LASP-1 phosphorylation by Src kinase is associated with platelet activation, translocation of LASP-1 to focal contacts and cytoskeleton rearrangement. 14 These observations imply a dual function of LASP-1 in terms of a structural scaffold at focal adhesions and a signal transducer conveying information from the cell surface to the nucleus.
Here we report that LASP-1 phosphorylation by PKA decreases LASP-1 binding to focal contact proteins, enhances binding to the novel identified LASP-1-shuttling partner zona occludens protein 2 (ZO-2) and controls nuclear translocation. The data substantiate LASP-1 as an additional target in antitumor strategies.
RESULTS

LASP-1 contains a conserved nuclear export signal (NES) between residues 71 and 77
We have previously shown that LASP-1 shuttles between cytosol and nucleus. 9, 15 To verify this dynamic process, MDA-MB231 breast cancer cells were treated with leptomycin B, a specific inhibitor of Crm-1-dependent nuclear export. 16 The subcellular localization of endogenous LASP-1 was then analyzed by direct immunofluorescence. Consistent with previous reports in resting cells, LASP-1 was primarily found in the cytosol and at lamellipodia of untreated cells (Figure 1a) . Upon cell treatment with leptomycin B, a nuclear LASP-1 accumulation was observed (Figure 1a) , pointing to the presence of a hydrophobic NES within the LASP-1 protein. Indeed, a search of the LASP-1 1 protein sequence by the NetNES prediction program (http:// www.cbs.dtu.dk/services/NetNES-1.1) revealed a leucine-rich sequence around amino acid leucine-74 (NLRL 74 KQQ) that is characteristic for a Crm-1-dependent NES, and is conserved from human to mouse (Figure 1b) .
To assess the potential importance of this putative NES, we expressed LASP-1 wild type and a LASP-1 variant that harbors a mutation in the putative NES signal sequence (LASP-L74A) in PtK2 cells (a cell line with negligible LASP-1 expression) and analyzed their nuclear localization. The wild-type protein was mainly localized in the cytosol (Figure 2a ) and showed an enrichment in the nucleus after leptomycin B treatment (Figure 2b) , whereas the LASP-1 L74A NES mutant accumulated in the nucleus even in the absence of leptomycin B (Figure 2c ). Western blot detection of LASP-1 in cytosolic and nuclear PtK2 cell fractions verified the immunocytochemical data ( Figure 2d ) and further supported a shuttling of LASP-1 between cytosol and nucleus.
Phosphorylation-dependent nuclear import of LASP-1 To explore the mechanisms underlying the dynamic regulation of LASP-1 nucleo-cytoplasmic shuttling, LASP-1 western blot analyses of cytosolic and nuclear fractions from BT-20 and MDA-MB231 cancer cells were performed. As it was shown earlier that PKA phosphorylation at Ser-146 enhances LASP-1 mobility, cells were preincubated with the PKA activator forskolin. 12 We detected a significant increase in nuclear LASP-1 upon forskolin stimulation in both the breast cancer cell lines (shown for MDA-MB231 in Figure 2e ).
To characterize the subcellular distribution of phosphorylated LASP-1, we utilized a phospho-antibody specific for Ser-146 (pLASP-S146) (Supplementary Figure S1) . Reprobing the blots with this pLASP-S146 antibody revealed a concomitant nuclear accumulation of the phosphorylated protein. Purity of the fractions was controlled by probing western blot membranes for the nuclear marker proteins Lamin A þ B and the cytoplasmic marker protein GAPDH (Figure 2e ).
Dephosphorylation of LASP-1 by PP2B As the Ser-146 phosphorylation by PKA seemed to have a crucial role in LASP-1 nucleo-cytoplasmic shuttling, we next determined the phosphatase involved in LASP-1 Ser-146 dephosphorylation. For these studies, purified recombinant LASP-1 was phosphorylated by PKA at Ser-146 and was incubated with different recombinant phosphatases. 12 In contrast to PP1, PP2A and PP2C, PP2B was very effective in dephosphorylating LASP-1 at Ser-146 (Figure 3a ). In line with this finding, the specific PP2B inhibitor cypermethrin blocked the dephosphorylation of LASP-1 by PP2B (Figure 3b ). For in vivo analysis, washed human platelets known to express PP1, PP2A and PP2B 17 were treated with 100 nM calyculin A (PP1 and PP2A inhibitor), 1 nM cypermethrin (PP2B inhibitor) or 0.1 nM NIPP (PP1 inhibitor) for 60 min. Phosphorylation of LASP-1 at Ser-146 was only observed after cypermethrin treatment ( Figure 3c ), indicating that PP2B is the primary enzyme responsible for dephosphorylating LASP-1 in vivo.
Identification of ZO-2 as a novel LASP-1-binding partner As LASP-1 sequence analysis revealed no nuclear localization signal, which mediates the nuclear import of most soluble cytoplasmic proteins, 18 the association of LASP-1 with a nuclearshuttling protein is likely. To identify factors that promote LASP-1 nuclear import, we used glutathione-S-transferase (GST)-tagged LASP-1 and MDA-MB231 cell lysate for an affinity purification approach. Analysis of the proteins that bound specifically to GST-LASP-1 by SDS-PAGE revealed the presence of several recurrent proteins that were subsequently identified by mass spectrometric analysis (Supplementary Figure S2) . Candidate 1 was identified as zyxin (Q15942), a previously known LASP-1-binding partner. 19 The second protein band from the affinity purification comprised dynamin-1 (Q05193) and dynamin-2 (P50570), again well-known LASP-1-binding proteins. 20 Finally, the 170-kDa protein was identified as ZO-2 (Q9UDY2), a tight junction protein with nuclear-cytoplasmic distribution. 21 The results from the mass spectrometric analysis were confirmed by western blot experiments ( Figure 4a ). Zyxin, ZO-2 and the also known LASP-1-binding partner LPP 22 were found in eluates from GST-LASP-1-loaded beads. We also detected F-actin, a prominent LASP-1-binding partner. 8 However, while F-actin association was also observed with the GST control beads, zyxin, LPP and ZO-2 binding were specific to GST-LASP-1 ( Figure 4a ). Western blot analysis of eluates after immunoprecipitation with ZO-2 antibody confirmed the novel interaction between LASP-1 and ZO-2 ( Figure 4b ).
Characterization of the LASP-1/ZO-2 interacting domains It was described earlier that zyxin and LPP interact with the C-terminal SH3 domain of LASP-1. 19 To identify the LASP-1 region involved in ZO-2 binding, we generated expression plasmids that either encoded GST fused to full-length LASP-1 (LASP wild type) or mutants lacking the SH3 domain (LASP-DSH3) or the N-terminal LIM domain (LASP-DLIM) and performed pull-down assays with platelet homogenate and MDA-MB231 cell lysate. Although LASP-DLIM retained its binding activity to zyxin, LPP and ZO-2, the LASP-DSH3 mutant was not capable of binding and precipitating any of the three proteins; clearly indicating that ZO-2 binds to the SH3 domain in LASP-1 ( Figure 4a ).
Next, we mapped the LASP-1-binding site within the ZO-2 protein sequence. SH3 domains are known to bind to proline-rich sequences containing the characteristic PPxP motif in which P is usually a proline residue and x a hydrophobic amino acid. 23 When using the SH3 hunter program (http://cbm.bio.uniroma2.it/SH3-Hunter), we discovered two adjacent putative SH3 domain interaction sites in the C-terminus of human ZO-2: KPDPGPT (amino acids (aa) 1103-1109) and PPEPQK (aa 1116-1121). To ZO-2 WT and the ZO-2 mutants P1106A, P1116A and P1106/1116A were expressed in MBA-MB231 cells, followed by pull-down (ZO-2 PD) with full-length GST-LASP-1 (d) ZO-2 binding to LASP-1 is phosphorylation-independent. MDA-MB231 homogenate was incubated with GST beads bound to full-length LASP-1 (WT), full-length LASP-1 phosphorylated by PKA (pLASP) or the LASP-1 phosphomimicking mutant (S146D). After pulldown, phosphorylation-specific binding of proteins was analyzed by anti-zyxin, anti-LPP and anti-ZO-2 western blotting. Interestingly, the pLASP antibody also recognizes the phosphomimicking sequence in LASP-1-S146D albeit with lower affinity.
analyze the impact of these two motifs on LASP-1 binding, we generated three mutants in which specific proline residues were replaced by alanines: ZO-2 P1106A, ZO-2 P1116A and the double mutant ZO-2 P1106A/P1116A. Using these constructs, we performed GST pull-down experiments with MDA-MB231 homogenate. Although binding was observed with wild-type ZO-2 and ZO-2 P1116A, western blot analysis revealed no LASP-1 interaction with ZO-2 P1106A and the ZO-2 P1106A/P1116A double mutant, assuming that the LASP-1 SH3 recognition motif is present in the first proline-rich PPxP motif (aa 1103-1106) of ZO-2 (Figure 4c) .
To determine if ZO-2, zyxin and LPP bind to the same region in the SH3 domain of LASP-1, indirect competitive overlay experiments were performed in which recombinant N-terminal prolinerich fragments of zyxin (aa 1-149) and LPP (aa 1-109), both known to bind to LASP-1, 22 were mixed with the proline-rich sequence containing fragment of ZO-2 (aa 878-1167). Binding of ZO-2 to LASP-1 is reduced to about 50% in the presence of equal concentrations LPP or zyxin (Supplementary Figure S3) . Thus, the binding site for ZO-2 appears to be the same or in close proximity to that for zyxin and LPP.
Impact of Ser-146 phosphorylation on binding of LASP-1 to LPP, zyxin and ZO-2 To address a putative linkage between the LASP-1 phosphorylation on Ser-146 by PKA and binding of interacting partners to the identified SH3 domain, we performed GST pull-down experiments using MDA-MB231 cell lysate with wild-type LASP-1 or LASP-1 phosphorylated at Ser-146 by PKA. In addition, a phosphorylationmimicking mutant LASP-S146D was used. 12 Western blot detection of purified proteins demonstrated a decreased binding of zyxin and LPP to LASP-1 phosphorylated at Ser-146, whereas the binding to ZO-2 was not impaired by this posttranslational modification (Figure 4d ).
Co-localization of LASP-1 and ZO-2 in the nucleus To further characterize the LASP-1/ZO-2 interaction, we examined the subcellular localization of the protein complex using the in situ proximity ligation assay (PLA). The assay allows precise detection of protein-protein interactions. Two primary antibodies raised in different species recognize the target antigens of interest. Specific secondary antibodies, called PLA probes, each with a unique short DNA strand, bind to the primary antibodies. When the PLA probes are in close proximity, the DNA strands can interact, form a circle, are amplified, and the replicants are fluorescence-labeled and detected with a fluorescence microscope. 24 Immunfluorescence analysis of MDA-MB231 cells detected the LASP-1/ZO-2 complex (visualized as red dots) in the nucleus and in focal contacts but not along cell borders or lamellipodia (Figure 5a) . A Z-scan through the nucleus using confocal microscopy confirmed the nuclear localization (Figure 6a) . In each level analyzed, a few red spots were observed in the nucleus of the cell, which appeared and disappeared sequentially during the analysis from the bottom to the top of the cell (Figure 6a) . Interestingly, we also observed a less pronounced but definite LASP-1/LPP interaction in the nucleus of the MDA-MB231 cells, whereas the LASP-1/zyxin interaction was exclusively detected in the cytosol at focal adhesions and perinuclear (Figure 5a ).
Control experiments with LASP-1/NFkappaB (no interaction, negative control) showed no fluorescence signals and confirmed the specificity of the LASP-1/protein interactions visualized using the in situ PLA (Figure 5a ).
To further analyze the phosphorylation-dependent LASP-1/ZO-2 interaction, we performed PLA experiments with the selfgenerated polyclonal LASP-1-specific antibodies directed against phosphorylated LASP-146 (pLASP) and dephosphorylated LASP-146 (dpLASP). As seen in Figure 6b , ZO-2/LASP-1 interaction is mainly observed with the pLASP-1 antibody, whereas LPP is preferentially bound to dpLASP-1.
As PKA-mediated phosphorylation of Ser-146 by PKA impaired binding of LASP-1 to zyxin and LPP and facilitated interaction with ZO-2, forskolin stimulation should increase the level of nuclear LASP-1 together with ZO-2. Indeed, we detected a significant increase of nuclear LASP-1/pLASP-1 and ZO-2 by western blot analysis of the nuclear and cytosolic fractions in MDA-MB231 cells after forskolin treatment (Figure 5b ). Knockdown of ZO-2 attenuated nuclear LASP-1 concentration and confirmed ZO-2 as nuclear LASP-1-shuttling partner (Figure 5c ).
DISCUSSION
Recent studies have described an overexpression of LASP-1 in various cancer entities and have implied an essential role of LASP-1 in cell proliferation and migration. 4, 6, 7, 25 Interestingly, Regulation of nucleo-cytoplasmatic LASP shuttling S Mihlan et al immunohistochemical analyses also indicate an enhanced nuclear localization of LASP-1 in breast cancer and medulloblastoma, which correlates with node positivity and poor long-term survival of the patients. 7, 9, 15 Furthermore, an association between elevated nuclear LASP-1 levels and mutations of the p53 tumor-suppressor gene is observed in hepatocellular carcinoma, invasive breast carcinoma, urothelial carcinoma and medulloblastoma, but not in glioblastoma or chorioncarcinoma. 15 In addition, microRNAs are discussed to control LASP-1 expression. 25, 26 In this report, we present data elucidating the previously unknown signaling pathway that regulates the transport of LASP-1 from the cytosol to the nucleus. Under resting conditions, LASP-1 is mainly associated with the plasma membrane and with focal contacts by binding to F-actin, LPP, zyxin and the newly identified binding partner ZO-2 ( Figure 7) . Stimulation of the cell results in PKA-mediated phosphorylation of LASP-1 at Ser-146 that impairs its binding toward cytoskeleton-associated zyxin and LPP but leaves interaction with the nuclear shuttle protein ZO-2 unaffected. Interestingly, also zyxin becomes phosphorylated by PKA, thus strengthens binding of zyxin to cell-cell contacts and simultaneously facilitates repulsing of LASP-1. 27 Subsequently, a fraction of the cytoplasmic LASP-1/ZO-2 complex transmigrates into the nucleus. In contrast, dephosphorylation at Ser-146 by PP2B causes a return of cytoplasmic LASP-1 back to focal contacts and the plasma membrane ( Figure 7) .
In malignant breast cancer, the concentration of active PKA is four times higher than in normal breast and causes a hyperphosphorylation of PKA substrates including the CREB transcription factor 28 and the estrogen receptor. 31 Therefore, known upregulation of LASP-1 levels in breast cancer cells in combination with LASP-1 hyperphosphorylation by PKA at Ser-146 and subsequent nuclear import might be crucial for its oncogenic potential.
Because LASP-1 lacks a known nuclear import signal, the presence of a specific binding partner for its nuclear shuttling was predicted. Although several LASP-1-binding partners such as dynamin, zyxin, LPP, palladin, Krp1 and Pro-Il-16 have been identified, 2 none of them has been shown to regulate the nuclear localization of LASP-1. The newly identified LASP-1-interacting protein, ZO-2, represents a cytosolic scaffold that regulates the assembly of tight junctions. In addition, it has been reported to accumulate transiently in the nucleus, where it binds to the DNAscaffolding factor SAFB and the transcription factors fos, jun and c-myc. 21, [29] [30] [31] Furthermore, ZO-2 regulates nuclear transport of YAP2 (Yes kinase-associated protein 2). Like LASP-1, YAP2 exhibits In situ immunofluorescence detection of endogenous LASP-1/ protein complexes using PLA. PhosphoLASP-1 (pLASP) and dephosphoLASP-1 (dpLASP) binding to ZO-2 and LPP was visualized by staining cells with PLA probes directed against pLASP-1 or dpLASP-1 and LPP or ZO-2, followed by ligation and rolling circle amplification. Each red spot represents a LASP-1/protein interaction in resting MDA-MD231 breast cancer cells. Cytoskeleton was counterstained with phalloidingreen-labeled antibody to actin (green) and the nuclei were stained with DAPI (blue). Scale bars 20 mm. Figure 7 . Proposed mechanism of PKA-induced LASP-1 translocation. Under basal conditions, LASP-1 is associated with F-actin, zyxin and ZO-2 at the plasma membrane and focal contacts. A minor cytosolic fraction shuttles between the cytoplasm and the nucleus. Upon LASP-1 phosphorylation at Ser-146 by (PKA) activation via G-coupled receptor (GCRP), LASP-1 binding to F-actin and zyxin is impaired and the protein detaches from the plasma membrane, forms a complex with ZO-2 and translocates into the nucleus. In return, nuclear export is regulated by reversible binding to the exportin Crm-1 via the NES in LASP-1. Activation of protein phosphatase PP2B by PKA results in the dephosphorylation of LASP-1 and return of the protein to the plasma membrane.
no nuclear import signal and requires ZO-2 binding to shuttle into the nucleus. 32 Although YAP2 interacts with the first PDZ domain in the N-terminal of ZO-2, LASP-1 binds to the ZO-2 proline-rich C-terminus, pointing to the potential of a tripartite complex consisting of LASP-1, ZO-2 and YAP2.
What is the function of LASP-1 in the nucleus? We speculate that nuclear LASP-1 acts indirectly as a transcriptional co-factor, although the zinc-finger containing LIM domain in LASP-1 in principle offers a possibility for direct DNA binding and gene regulation. 33 LASP-1 might also regulate the function of nuclear F-actin, which is involved in chromatin remodeling and assembly of the transcription machinery. 34 In summary, we characterized the nucleo-cytoplasmatic shuttling of LASP-1, identified a hitherto unknown NES within the protein and discussed the nuclear accumulation of the protein in cancer cells. Our data demonstrate that PKA-mediated phosphorylation of LASP-1 is crucial for its cellular distribution. Moreover, we found that binding to ZO-2 is essential for LASP-1 nucleo-cytoplasmatic shuttling, possibly enabling LASP-1 to transmit extracellular signals into the nucleus and thereby to exert its potential role in regulation of gene expression. Further work will be necessary to define this putative new function of nuclear LASP-1 in detail.
MATERIALS AND METHODS
Lentivirus production
MDA-MB231 cells expressing inducible non-silencing control shRNA and ZO-2 shRNA were generated using lentiviral infection. The pTIPZ-shRNAmir plasmids (Open Biosystems, Huntsville, AL, USA) expressing non-silencing control shRNA or ZO-2-specific shRNA (sequence 5 0 -CTTCACGAAGGAGACA-TAA-3 0 ) were packaged into lentiviral particles in HEK297T cells, and MDA-MB231 cells were infected with the particles following the manufacturer's protocols. Stable cell lines were selected for resistance to puromycin (2 mg/ml) and single cells were selected to generate clonal cell lines with a ZO-2 knockdown X90% after 2 days of doxycyclin treatment (0.5 mg/ml).
Immunofluorescence
For immunofluorescence microscopy, cells were grown until 70% confluence on glass coverslips. Cells were fixed in 4% (w/v) paraformaldehyde in phosphate-buffered saline, permeabilized with 0.1% (w/v) Triton X-100 in phosphate-buffered saline and then stained with affinity-purified LASP-1 antibody (diluted 10 mg/ml) 9 and Oregon green phalloidin antibody (1:50, Invitrogen, Karlsruhe, Germany) followed by secondary Cy3-labeled anti-rabbit antibody (1:500, Dianova, Hamburg, Germany).
Preparation of nuclear and cytosolic cell fractions
Human breast cancer cell lines were harvested at 80% confluence through trypsination. Isolation of nuclei and cytosol was carried out using NE-PER nuclear and cytoplasmic extraction reagents (Pierce, Bonn, Germany) following the manufacturer's instructions. Samples were solved in Laemmli sample buffer at a final concentration of 1 Â 10 6 cells/ml and stored at À 20 1C before western blot electrophoresis.
Phosphatase assays
Recombinant PP1, PP2A and PP2B were purchased from Calbiochem (Merck, Darmstadt, Germany) and PP2C was ordered from Biaffin (Kassel, Germany). All the phosphatases were tested for activity according to the data sheets following the manufacturer's instructions.
A total of 5 mg recombinant-purified GST-LASP-1 was phosphorylated for 30 min in the presence of 0.1 mg cyclic adenosine monophosphatedependent protein kinase catalytic subunit as described earlier. 12 After washing, the beads were divided in five equal aliquots for dephosphorylation analysis.
Dephosphorylation reactions were conducted with 0.2 U phosphatase for 20 min at 30 1C in 50 ml phosphatase assay buffer (50 mM Tris-HCl pH 7.2, 1 mM dithioerythritol, 5 mM MgCl 2 , 0.01% bovine serum albumin and 0.03% Nonidet P40; also containing 0.05 mg/ml calmodulin/0.5 mM CaCl 2 for PP2B or 20 mM MgCl 2 for PP2C). Dephosphorylated GST-LASP-1 was eluted off the beads by 5 min boiling in sample-loading buffer and analyzed by western blot. Inhibition of phosphatase activity by 100 nM calyculin A (PP1 and PP2A inhibitor), 1 nM cypermethrin (PP2B inhibitor), 0.1 nM NIPP (PP1 inhibitor) and 10 mM PTP1B inhibitor (all from Calbiochem) was determined by incubating the indicated compounds with the phosphatase before the addition of the labeled substrate or by incubating washed human platelets (3 Â 10 8 cells/ml) for 60 min with the phosphatase inhibitor. All the probes were analyzed for dephosphorylated LASP-1 by western blot.
Generation of LASP-1, ZO-2 mutants, N-terminal LPP and zyxin fragments A full-length cDNA for human LASP-1 (GenBank acession number X82456) was cloned into the pGEX4T1 vector (GE Healthcare, Freiburg, Germany). Point mutations within LASP-1 sequence (L74A and S146D) were performed using Stratagene QuickChange mutagenesis kit (La Jolla, CA, USA).
For generation of the LASP-DLIM (aa 64-261) and LASP-DSH3 (aa 1-190) deletion mutants, we used the internal NcoI and PstI restriction sites in the human LASP-1 cDNA, respectively. The fragments were recloned into pGEX4T1.All the mutants were verified by sequencing.
Full-length cDNA for human ZO-2 (GenBank accession number Q9UDY2.3) was obtained from imaGenes (Berlin, Germany). Mutations within ZO-2 resulting both in single and double amino-acid substitutions (P1106A; P1116A, P1106/1116A) were performed using PCR-based sitedirected mutagenesis (Stratagene QuickChange mutagenesis kit). ZO-2 and its mutants were ligated into pGEX4T1 to generate GST-ZO-2 fusion proteins and into pcDNA3. All mutants were verified by sequencing.
N-terminal fragments of zyxin (aa 1-149) and LPP (aa 1-109) were a kind gift from Dr Matthias Reinhard (Immunoglobe, Himmelstadt, Germany).
Pull-down experiments
Human blood was drawn by venipuncture and mixed with citrate buffer (100 mM sodium citrate, 7 mM citric acid, 140 mM glucose and 15 mM EGTA; pH 6.5) in 5:1 ratio. The blood was centrifuged for 20 min at 300 g to get platelet-rich plasma. After 10 min centrifugation at 380 g, the platelet pellet was washed in citrate-glucose-salt (CGS) buffer (120 mM NaCl, 12.9 mM sodium citrate, 30 mM D-glucose; pH 6.5) and centrifuged again (380 g,10 min). The platelet pellet was resuspended in Hepes buffer (10 mM Hepes pH 7.4, 10 mM glucose, 145 mM NaCl, 5 mM KCl and 1 mM MgCl 2 ) to give a concentration of 4.5 Â 10 8 cells/ml and mixed 1:3 with 3 Â lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 3 mM EGTA, 3% Triton X-100 and Complete Mini). After 30 min rotation at 4 1C, cells were lysed with a 291/2 gauge needle and centrifuged for 30 min at 20 000 g. The supernatant was incubated for 2 h with the respective GST beads, washed three times with phosphate-buffered saline and analyzed by SDS-PAGE and western blot.
MDA-MB231 cells (1 Â 10 6 cells/ml) were pelleted by centrifugation, resuspended in lysis buffer (10 mM Hepes pH 8.1, 1 mM KCl, 1.5 mM EDTA, 200 mM sucrose and Complete Mini) and lysed on ice for 30 min. After a freeze/thaw cycle the lysate was centrifuged again for 10 min. The supernatant was incubated with the respective GST beads for 2 h. Beads were then treated as described previously.
Coimmunoprecipitation
Platelets or MDA-MB231 were lysed with radioimmunoprecipitation assay (RIPA) buffer (20 mM Tris pH 7.4, 150 mM NaCl, 1% sodium deoxycholate, 1% Triton X-100, 0.1% SDS, 1 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 10 mM EDTA and protease inhibitor mixture). After centrifugation (14000 g for 30 min) the supernatant.fractions were precleared by continuous rotation with protein A/G-Sepharose beads (GE Healthcare) for 30 min at 4 1C. Immunoprecipitation was performed by rotation of 500 ml precleared supernatant with 2 mg of the monoclonal ZO-2 antibody (New England Biolabs, Frankfurt, Germany) for 2 h at 4 1C followed by incubation with protein A/G-Sepharose for another 1 h at 4 1C. The immunocomplex was washed three times with ice-cold lysis buffer and prepared for SDS-PAGE as described above.
Overlay experiments
A total of 0.1 mg GST-LASP-1 was blotted on nitrocellulose (Schleicher und Schuell, Kassel, Germany) and blocked with 3% nonfat dry milk (Bio-Rad, Munich, Germany) in 10 mM Tris, pH 7.5, 100 mM NaCl and 0.1% (w/v) Tween 20. For overlay experiments, membrane lanes were incubated overnight at 4 1C with 10 mM ZO-2 alone or 10 mM ZO-2/LPP or 10 mM ZO-2/zyxin. After gentle washing, lanes were incubated first with polyclonal ZO-2 antibody (diluted 1:1000, New England Biolabs) followed Regulation of nucleo-cytoplasmatic LASP shuttling S Mihlan et al
